CN114028291B - Composition for improving dark eye circles and preparation method and application thereof - Google Patents

Composition for improving dark eye circles and preparation method and application thereof Download PDF

Info

Publication number
CN114028291B
CN114028291B CN202111444022.3A CN202111444022A CN114028291B CN 114028291 B CN114028291 B CN 114028291B CN 202111444022 A CN202111444022 A CN 202111444022A CN 114028291 B CN114028291 B CN 114028291B
Authority
CN
China
Prior art keywords
parts
composition
eye
hyaluronic acid
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111444022.3A
Other languages
Chinese (zh)
Other versions
CN114028291A (en
Inventor
郭潇潇
李楚忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Huanya Cosmetic Science and Technology Co Ltd
Original Assignee
Guangzhou Huanya Cosmetic Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Huanya Cosmetic Science and Technology Co Ltd filed Critical Guangzhou Huanya Cosmetic Science and Technology Co Ltd
Priority to CN202111444022.3A priority Critical patent/CN114028291B/en
Publication of CN114028291A publication Critical patent/CN114028291A/en
Application granted granted Critical
Publication of CN114028291B publication Critical patent/CN114028291B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/592Mixtures of compounds complementing their respective functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

The invention belongs to the technical field of cosmetics, and discloses a composition for improving dark circles, and a preparation method and application thereof. The composition comprises the following components: tea fermentation liquor, white peony root extract, inonotus obliquus extract and hyaluronic acid composition. By the mutual synergistic effect of the tea fermentation liquid, the white peony root extract, the inonotus obliquus extract and the hyaluronic acid composition, the composition and the cosmetic containing the composition provided by the invention are applied to eyes, can decompose pigment formed on the eyes, fade black eye circles and reduce the area of the black eye circles, and further quickly improve the black eye circles; has the characteristics of mild and no stimulation to skin, simple preparation method and easy realization of industrialization.

Description

Composition for improving dark eye circles and preparation method and application thereof
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a composition for improving dark circles, and a preparation method and application thereof.
Background
Compared with skin of other parts of the body, the eye skin is weaker, low in tolerance, easy to dry and lack, and is easy to generate pigment type, blood vessel type or structural type black eye rings under the conditions of eye overstrain and insufficient oxygen supply.
Related research products for improving eye problems are increasing at present. Although the eye drops have the eye problems of fading dark circles, removing edema and the like, the eye drops also have the problems of irritation, incomplete action effect, no synergistic effect and the like.
Therefore, there is a need for an eye product that is mild and non-irritating and has efficacy in improving dark circles under the eyes.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art described above. Therefore, the invention provides a composition for improving black eye circles, a preparation method and application thereof, and the composition is mild and non-irritant and can improve the black eye circles.
In a first aspect of the present invention, there is provided a composition for improving dark circles, the composition comprising the following components: tea fermentation liquor, white peony root extract, inonotus obliquus extract and hyaluronic acid composition.
The records in the book "materia medica shiyi" (herbal medicine for the deceased) are: 'the tea is thin after being eaten for a long time and the human fat is removed'. The tea extract contains rich active ingredients such as tea polyphenol, caffeine, saccharides and amino acids, has comprehensive nutrition, and can delay aging; the tea extract is rich in flavonoids and anthocyanin, can remove free radicals, and has strong oxidation resistance; the caffeine can enhance blood vessel microcirculation, and can promote metabolism of skin around eyes and prevent pigmentation when applied to eyes. The fermented tea extract contains various amino acids, micromolecular peptides and other nutrients, and can resist oxidation and aging; and has the advantages of small molecular weight, easy absorption and permeation, etc.
White peony root, the active ingredient of which is paeoniflorin, has the effects of tonifying qi, benefiting blood, whitening and moistening skin; the white peony root extract has positive effects on the elimination of free radicals, the inhibition of elastase, the promotion of the activity of cathepsin and the like; the white peony root is extracted and applied to eyes, can relieve skin pigmentation, and is widely applied to cosmetics such as whitening, skin brightening, anti-aging and the like.
Inonotus obliquus extract is a product obtained by extracting Inonotus obliquus with subcritical water, can remove free radicals, protect cells, help to strengthen connection between skin and epidermis, and can reduce fatigue signs according to eye contour; meanwhile, the composition can stimulate the generation of vascular structural protein, strengthen a microvascular network, reduce vascular leakage, prevent inflammatory injury, strengthen a health barrier and prevent dark circles under the eyes.
Hyaluronic acid with different molecular weights is contained in the hyaluronic acid composition; macromolecular hyaluronic acid can stay on the surface of the skin, so that rapid water replenishing is realized; the micromolecular hyaluronic acid can permeate the inside of the skin to realize deep water locking; after acetyl is introduced into the acetylated sodium hyaluronate, the affinity to the skin can be enhanced, the epidermal cell proliferation is promoted, the skin barrier is repaired, the collagen hydrolase is inhibited, and the skin elasticity is enhanced; therefore, the hyaluronic acid composition is similar to a three-dimensional sponge and a slow hyaluronic acid filling technology, and realizes water replenishing layer by layer and three-dimensional filling.
The invention follows the principle of progressive and synergistic interaction, removes free radicals and decomposes pigments formed on eyes through synergistic interaction of tea fermentation liquid and white paeony root extract, and has the characteristics of mildness and high efficiency; by multiplying the efficacies of the tea fermentation liquid and the inonotus obliquus extract, the tea fermentation liquid further contributes to the contraction of capillary vessels around eyes, the improvement of skin microcirculation around eyes and the revitalization of skin around eyes, thereby lightening the vascular black eye formed by staying up all the night; through the cooperative water replenishing, shrinking and three-dimensional supporting of the hyaluronic acid composition, the inonotus obliquus extract and the tea fermentation liquid, the sunken eyelids are strengthened and the eye contour is strengthened, the structural black eye is solved, and the effect of comprehensively and quickly improving the black eye is achieved.
Based on the formation reason of the black eye, the black eye is improved in multiple ways, the skin is easy to absorb, the effect is more obvious, the black eye is mild and free of side effects, the black eye removing effect and the eye skin tightening and elasticity recovering effect are achieved by adjusting the component weight through the synergistic and complementary effects of the components, and the black eye removing and restoring agent is suitable for wide black eye consumer groups.
According to some embodiments of the invention, the tea fermentation broth is obtained by inoculating tea with a bacterial species.
According to some embodiments of the invention, the bacterial species is selected from at least one of bifidobacteria, rhizopus, yeasts, aspergillus. Preferably, the bacterial species is a bifidobacterium.
According to some embodiments of the invention, the tea is selected from at least one of green tea, white tea, oolong tea, black tea, pu' er tea, dark tea, persimmon leaf tea. Preferably, the tea is Pu' er tea.
According to some embodiments of the invention, the pu 'er tea is Yunnan pu' er tea with high anthocyanin content. Preferably, the Pu' er tea is purple tea.
According to some embodiments of the invention, the tea fermentation broth is prepared by: soaking tea, and sterilizing to obtain soaking solution; selecting and activating bifidobacteria, carrying out expanded culture, inoculating the bifidobacteria in a culture medium containing the soak solution, a carbon source and a nitrogen source, and carrying out fermentation culture; and taking the fermented supernatant for sterilization to obtain the tea fermentation liquor. Preferably, the temperature of the soaking is 80-90 ℃.
According to some embodiments of the invention, the white peony extract is an extract of white peony root with water and/or alcohol. According to some embodiments of the invention, the alcohol is at least one of methanol, ethanol, propanol or butanol. According to some embodiments of the invention, the alcohol is 65-70% ethanol.
According to some embodiments of the invention, the hyaluronic acid comprises hyaluronate with a molecular weight of 1000-1800kDa, hydrolyzed hyaluronate with a molecular weight of less than 10kDa and acetylated hyaluronate.
According to some embodiments of the present invention, the mass ratio of the hyaluronic acid salt, the hydrolyzed hyaluronic acid salt, and the acetylated hyaluronic acid salt is 1 (0.95-1.05): (0.95-1.05). Preferably, the mass ratio of the hyaluronate, the hydrolyzed hyaluronate and the acetylated hyaluronate is 1.
According to some embodiments of the invention, the hyaluronic acid salt is sodium hyaluronate or potassium hyaluronate.
According to some embodiments of the invention, the hydrolyzed hyaluronate is hydrolyzed sodium hyaluronate or hydrolyzed potassium hyaluronate.
According to some embodiments of the invention, the acetylated hyaluronate is acetylated sodium hyaluronate or acetylated potassium hyaluronate.
According to some embodiments of the invention, the composition comprises the following components in parts by weight: 50-70 parts of fermentation liquor, 5-10 parts of white peony root extract, 1-5 parts of inonotus obliquus extract and 0.1-1 part of hyaluronic acid composition.
According to some embodiments of the invention, the composition further comprises a solvent, the solvent being at least one of butylene glycol, glycerol, or 1, 3-propanediol. Preferably, the solvent is butylene glycol. Preferably, the composition comprises 15 to 25 parts by weight of solvent. Preferably, 15-25 parts of butanediol are included.
According to some embodiments of the invention, the composition further comprises a preservative which is at least one of p-hydroxyacetophenone, potassium sorbate, sodium benzoate, phenoxyethanol, or ethylhexyl glycerin. Preferably, the composition comprises 0.2 to 0.5 parts by weight of a preservative.
A second aspect of the present invention provides a process for the preparation of the above composition, said process comprising the steps of: mixing the components, and heating to obtain the composition.
Specifically, according to some embodiments of the present invention, the preparation method comprises the steps of: mixing the white peony root extract, the hyaluronic acid composition, the tea fermentation liquor and the inonotus obliquus extract, and heating to be uniform to obtain the composition.
According to some embodiments of the invention, the method of preparing comprises the steps of: mixing the white peony root extract, the hyaluronic acid composition and butanediol, stirring uniformly, and adding sodium benzoate; stirring, adding fermentation broth and Inonotus obliquus extract, and stirring at 55-60 deg.C; and cooling to room temperature after uniformly stirring to obtain the composition.
According to some embodiments of the invention, the method of preparing further comprises a method of preparing the white peony root extract. The preparation method of the white peony root extract comprises the following steps: pulverizing radix Paeoniae alba and sieving; extracting with 65-70% ethanol at 60 deg.C for 3 times to obtain first extractive solution; and purifying, collecting, concentrating and air-drying the first extracting solution by macroporous resin to obtain the white paeony root extract.
According to some embodiments of the invention, the method of making further comprises a method of making the tea fermentation broth by sterilizing a tea infusion to obtain a tea infusion; selecting bifidobacterium for activation, carrying out expanded culture, inoculating the bifidobacterium into a culture medium containing the tea soak solution, a carbon source and a nitrogen source, and carrying out fermentation culture; filtering to obtain supernatant; and sterilizing the supernatant to obtain the tea fermentation liquor. Preferably, the tea is Pu' er tea. Preferably, the Pu 'er tea is Yunnan Pu' er tea. Preferably, the Pu 'er tea is Yunnan Pu' er tea with high anthocyanin content.
A third aspect of the present invention provides a cosmetic comprising the above composition.
According to some embodiments of the invention, the composition is present in the cosmetic product in an amount of 1% to 10% by weight.
According to some embodiments of the invention, the cosmetic is selected from at least one of a lotion, a serum, a cream, or a mask.
According to some embodiments of the invention, the cosmetic is at least one of an eye essence, an eye essence lotion, an eye mask or an eye cream.
In a fourth aspect the present invention provides the use of a composition as described above in the manufacture of a product for improving dark circles.
Therefore, the beneficial effects of the invention include:
(1) The composition provided by the invention is applied to eyes through the mutual synergistic effect of the tea fermentation liquid, the white paeony root extract, the inonotus obliquus extract and the hyaluronic acid composition, and can decompose pigment formed in the eyes and fade black eye circles, so that the effect of the black eye circles is rapidly improved.
(2) The composition provided by the invention is applied to eyes, is mild and non-irritant to skin, and can fade black eyes and reduce the area of the black eyes;
(3) The preparation method of the composition provided by the invention is simple and easy to realize industrially.
Drawings
The following description of the embodiments of the present invention will be made with reference to the accompanying drawings.
Fig. 1 is a diagram showing the effect of eyes after using the eye cream provided in example 9 of the present invention;
fig. 2 is a graph showing evaluation of the effect of the eye cream provided in example 9 of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more clearly understood, the technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application.
The technical scheme provided by the embodiment of the application is described in the following with the accompanying drawings of the specification.
Example 1
The embodiment provides a composition, which comprises the following components in parts by weight: 20 parts of tea fermentation liquor, 1 part of white peony root extract, 0.5 part of inonotus obliquus extract, 0.3 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 37.9 parts of water.
The preparation method of the composition comprises the following steps:
(1) Preparing tea fermentation liquor; soaking Yunnan Pu' er tea with high anthocyanin content at 80-90 deg.C for sterilization to obtain tea soak solution; selecting Bacillus bifidus, activating, performing amplification culture, inoculating into fermentation culture medium containing the tea soaking solution, and performing fermentation culture; filtering, collecting supernatant, filtering, and sterilizing to obtain tea fermentation liquid;
(2) Preparing a white peony root extract; pulverizing radix Paeoniae alba and sieving; extracting with 65-70% ethanol at 60 deg.C for 3 times to obtain first extractive solution; purifying the first extractive solution with macroporous resin, collecting, concentrating, and air drying to obtain radix Paeoniae alba extract;
(3) Dispersing the hyaluronic acid composition and the white peony root extract with butanediol, and then dissolving sodium benzoate to obtain a first mixture;
(4) Adding the rest components into the first mixture, and stirring uniformly to obtain a second mixture;
(5) Heating the second mixture to 55-60 ℃, and stirring uniformly; then cooling to obtain the composition.
The embodiment also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example 1.
The preparation method of the eye cream comprises the following steps: adding phase A into an emulsifying pot, heating to 75-80 ℃, and stirring and dispersing uniformly; adding phase B into oil phase pan, heating to 75-80 deg.C, stirring and dissolving completely; pumping phase B into emulsifying pan, homogenizing for 3-5min, and stirring; cooling to 55-60 deg.C, adding phase C, and homogenizing for 1-3min; cooling to 40-45 deg.C, adding phase D, homogenizing for 1-3min, and stirring; cooling to below 37 ℃, and defoaming to obtain the eye cream.
Example 2
The embodiment provides a composition, which comprises the following components in parts by weight: 20 parts of tea fermentation liquor, 10 parts of white peony root extract, 0.5 part of inonotus obliquus extract, 0.3 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 48.9 parts of water.
The preparation of the composition was the same as that of the composition of example 1.
The embodiment also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of ethylene diamine tetraacetic acid (EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) steareth ether (i.e. BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 3
The embodiment provides a composition, which comprises the following components in parts by weight: 20 parts of tea fermentation liquor, 10 parts of white peony root extract, 5 parts of inonotus obliquus extract, 0.3 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 44.4 parts of water.
The preparation of the composition was the same as that of the composition of example 1.
The embodiment also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of ethylene diamine tetraacetic acid (EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 4
This example provides a composition, which differs from example 1 in that it comprises the following components in parts by weight: 50 parts of tea fermentation liquor, 1 part of white peony root extract, 0.5 part of inonotus obliquus extract, 0.3 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 27.9 parts of water.
The preparation of the composition was the same as that of the composition of example 1.
The embodiment also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 5
This example provides a composition, which differs from example 1 in that it comprises the following components in parts by weight: 50 parts of tea fermentation liquor, 10 parts of white peony root extract, 0.5 part of inonotus obliquus extract, 0.3 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 18.9 parts of water.
The preparation of the composition was the same as that of the composition of example 1.
The embodiment also provides an eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 6
The embodiment provides a composition, which comprises the following components in parts by weight: 50 parts of tea fermentation liquor, 10 parts of white peony root extract, 5 parts of inonotus obliquus extract, 0.3 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 14.4 parts of water.
The preparation of the composition was the same as that of the composition of example 1.
The embodiment also provides an eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of ethylene diamine tetraacetic acid (EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 7
The embodiment provides a composition, which comprises the following components in parts by weight: 70 parts of tea fermentation liquor, 10 parts of white peony root extract, 5 parts of inonotus obliquus extract, 0.9 part of hyaluronic acid composition, 0.3 part of sodium benzoate and 13.8 parts of butanediol.
The preparation of the composition was the same as that of the composition of example 1.
The embodiment also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 8
The embodiment provides an eye cream which comprises a phase A: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 6 parts of the composition provided in example 7.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 9
The embodiment provides an eye cream which comprises a phase A: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 9 parts of the composition provided in example 7.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 10
The embodiment provides a composition, which comprises the following components in parts by weight: 10 parts of tea fermentation liquor, 0.05 part of white peony root extract, 0.05 part of inonotus obliquus extract, 0.03 part of hyaluronic acid composition, 0.3 part of sodium benzoate, 20 parts of butanediol and 69.57 parts of deionized water. The preparation of the composition was the same as that of the composition of example 1.
The present comparative example also provides an eye cream, which is different from example 1 in that the composition provided by the present comparative example is included.
Specifically, the eye cream comprises a phase A: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 11
The embodiment provides an eye cream which comprises a phase A: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 6 parts of the composition provided in example 10.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Example 12
The embodiment provides an eye cream which comprises a phase A: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) steareth ether (i.e. BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 9 parts of the composition provided in example 10.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Comparative example 1
The comparative example provides a composition comprising, in parts by weight: 63.8 parts of deionized water, 10 parts of white paeony root extract, 5 parts of inonotus obliquus extract, 0.9 part of hyaluronic acid composition, 0.3 part of sodium benzoate and 20 parts of butanediol.
The preparation of the composition was the same as that of the composition of example 1.
The comparative example also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this comparative example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Comparative example 2
The comparative example provides a composition comprising, in parts by weight: 70 parts of tea fermentation liquor, 5 parts of inonotus obliquus extract, 0.9 part of hyaluronic acid composition, 0.3 part of sodium benzoate and 20 parts of butanediol; 4.4 parts of deionized water.
The preparation of the composition was the same as that of the composition of example 1.
The comparative example also provides an eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of ethylene diamine tetraacetic acid (EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided by this comparative example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Comparative example 3
The comparative example provides a composition comprising, in parts by weight: 70 parts of tea fermentation liquor, 10 parts of white peony root extract, 0.9 part of hyaluronic acid composition, 0.3 part of sodium benzoate and 18.8 parts of butanediol.
The preparation of the composition was the same as that of the composition of example 1.
The comparative example also provides an eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of ethylene diamine tetraacetic acid (EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) steareth ether (i.e. BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided in this comparative example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Comparative example 4
The comparative example provides a composition comprising, in parts by weight: 70 parts of tea fermentation liquor, 10 parts of white peony root extract, 5 parts of inonotus obliquus extract, 0.3 part of sodium benzoate and 14.7 parts of butanediol.
The preparation of the composition was the same as that of the composition of example 1.
The comparative example also provides eye cream which comprises the following components in parts by weight: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of disodium ethylene diamine tetraacetate (namely EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) steareth ether (i.e. BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibirag 305 (i.e. SEPIGEL 305); and phase D: 0.3 parts phenoxyethanol, 0.12 parts triethanolamine, 3 parts of the composition provided by this comparative example.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Comparative example 5
The comparative example provides an eye cream which comprises a phase A: 78.53 parts of deionized water, 5 parts of glycerol, 0.02 part of ethylene diamine tetraacetic acid (EDTA-2 Na), 0.03 part of sodium hyaluronate, 0.2 part of carbomer and 0.5 part of p-hydroxyacetophenone; phase B: 1 part of polyoxyethylene (21) stearyl alcohol ether (i.e., BRIJ 721), 1.2 parts of behenyl alcohol, 0.8 parts of cetyl alcohol, 3 parts of meadowfoam seed oil, 3 parts of squalane, 0.5 parts of tocopheryl acetate, 2 parts of polydimethylsiloxane; and C phase: 0.8 parts of sibic 305 (i.e. SEPIGEL 305); and phase D: 0.3 part of phenoxyethanol and 0.12 part of triethanolamine.
The preparation method of the eye cream is the same as that of the eye cream in example 1.
Performance testing
1. Ocular skin color value test
The experimental principle is as follows: according to the skin color value L * The size of (D) is used to determine the color depth of the skin around the eyes, L * The larger the value, the lighter the color of the skin around the eyes, i.e., the more remarkable the effect of removing dark circles.
The experimental method comprises the following steps: screening 102 women aged 25-50 years and with deep dark circles as subjects, divided into 17 groups (experiment 1-12 and comparison 1-5) of 6 persons each; the corresponding eye creams were used for each group: experiments 1 to 12 were conducted using the eye creams provided in examples 1 to 12, respectively, and comparative examples 1 to 5 were conducted using the eye creams provided in comparative examples 1 to 5, respectively; the eye cream is applied to eyes in the morning and evening every day for 28 days.
The groups are respectively rested for 10 minutes in a constant temperature and humidity environment (air temperature: 21 +/-1 ℃, humidity: 50 +/-10%) on the 0 th day, the 14 th day and the 28 th day of using the eye cream, and then an eye skin color value test is carried out: taking the same position of lower eyelid of the tested person as the measurement region, taking VISIA-CR photograph with DICP-10-01 facial imager, and recording the skin color difference L * . And (3) data analysis: will be provided withAfter the 6 skin color difference values obtained by each group test are removed from the maximum value and the minimum value, the average value is taken as the skin color difference value corresponding to each group and is listed in table 1. Wherein
Figure GDA0003929411570000131
Is the color difference value at the 0 th day,
Figure GDA0003929411570000132
is the color difference value at the 14 th day,
Figure GDA0003929411570000133
is the color difference value at the 28 th day,
Figure GDA0003929411570000134
the difference between the color difference of day 14 and day 0,
Figure GDA0003929411570000135
the difference between the color difference of day 28 and day 0.
Table 1 skin color difference value detection results corresponding to each group
Figure GDA0003929411570000136
According to Table 1, the color difference values obtained from the tests of the experiments 1-12 and the comparison 1-5 are increased along with the continuous time. After 14 days of continuous use, the difference between the corresponding color differences of the experiment 1-12 groups is 1.41876 at most and 0.41783 at least; after 28 days of continuous use, the difference between the corresponding color differences of the experiments 1-12 groups is at most 2.7489 and at least 0.97765; the eye cream provided by the embodiment of the invention has certain efficacy on the black eye of a subject.
Comparative example 5 provided an eye cream to which the composition of the example of the present invention was not added, and the difference in color difference was only 0.02650 after 14 days of continuous use; after 28 days of continuous use, the difference of the color difference is only 0.04438; it was shown that the eye cream without the composition of the example of the present invention had little effect on improving dark circles.
The eye cream provided in comparative example 1 was not added with tea fermentation broth; the eye cream provided in comparative example 2 was not supplemented with white peony root extract; the eye cream provided in comparative example 3 was not added with the fomes fulva extract; hyaluronic acid was not added to the eye cream provided in comparative example 4; after 14 days of continuous use, the eye creams provided by the comparative examples 1 to 4 have higher effect on improving black eye than the corresponding effect of the comparative example 5, but much lower effect than the corresponding effects of the examples 1 to 12. It is shown that the effect of the embodiment of the invention on improving the dark circles is realized by the synergistic effect of the tea fermentation liquid, the white paeony root extract, the chaetomium globosum extract and the hyaluronic acid composition.
The eye creams provided in examples 7 to 9 contain 3 parts, 6 parts and 9 parts of the composition provided in example 7, respectively, and the difference in color difference after 28 days of continuous use is 2.56786, 2.67897 and 2.74890; examples 10 to 12 provided eye creams containing 3 parts, 6 parts and 9 parts of the composition provided in example 10, respectively, and having color difference values of 0.97765.1.27813 and 1.31670, respectively, after 28 days of continuous use, indicating that the more the part of the composition added to the eye cream, the better the black eye improvement effect; the proportions of the tea fermentation broth, the white peony root extract, the chaetomium globosum extract and the hyaluronic acid composition in the composition have a great relationship with the effect of improving the black eye, and the proportions of the components in the composition provided in example 7 are more favorable for improving the black eye.
In conclusion, the eye cream provided by the embodiment of the invention has the effect of obviously lightening black eye circles of a subject, and the effect is realized by synergistically enhancing the tea fermentation liquid, the white peony root extract, the inonotus obliquus extract and the hyaluronic acid composition within a certain content range, eliminating free radicals and improving eye microcirculation.
2. Improving contrast of black eye effect
A subject with a dark circle was screened, and the right eye was coated with the eye cream of example 9 and the left eye with the eye cream of comparative example 1, and the eye cream was continuously used for 28 days, and on the 28 th day of using the eye cream, the subject was allowed to rest for 10 minutes under a constant temperature and humidity environment (air temperature: 21. + -. 1 ℃ C., humidity: 50. + -. 10%) to obtain a control chart shown in FIG. 1.
According to the figure 1, after the test subject continuously uses the eye cream for 28 days, the color of the black eye circles of the eyes is obviously lightened, and the area of the black eye circles is also reduced to a certain extent. The eye cream provided by the embodiment of the invention has an improvement effect on black eyes of a subject.
3. Consumer self-evaluation test
The experimental method comprises the following steps: screening 50 subjects with deep black eyes, women with the ages of 25-65, who have no skin diseases and no skin allergy history, and dividing the subjects into two groups of 25 subjects; experiment 1 and experiment 2 groups the eye creams provided in example 9 and comparative example 1 were used, respectively; the product was evaluated twice a day, 28 days later, for the degree of stickiness to the skin, the rate of absorption of the cream, the color around the eyes, the area of dark circles, and the irritation score.
Evaluation criteria: each item has a total score of 5, the more refreshing the skin feel stickiness and the lower the score; the paste has higher absorption speed and higher fraction; the lighter the eye color, the lower the score; the larger the area of the black eye is, the higher the score is; the stimulation is small, the score is small, and the stimulation is no, and the score is 0.
The evaluation method comprises the following steps: the maximum and minimum values are removed and an average value is obtained. The evaluation results are shown in FIG. 2.
According to fig. 2, the eye cream provided by embodiment 9 of the present invention has characteristics of refreshing skin feel, smooth greasiness, fast absorption speed of the cream, fading of eye color, reduction of dark eye area, and no irritation; example 9 of the present invention has a better effect in the reduction of color around the eyes and the area of the black eye compared with comparative example 1.
Therefore, the eye cream provided by the embodiment of the invention can obviously reduce the color around eyes and reduce the area of black eyes, and has the effects of mildness and no stimulation.
Finally, it should be noted that the above embodiment modes are only used for illustrating the technical solutions of the present invention and not limiting, and although the present invention is described in detail with reference to the above preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention can be modified or substituted by equivalents without departing from the spirit and scope of the technical solutions of the present invention.

Claims (8)

1. The composition is characterized by comprising the following components in parts by weight: 50-70 parts of fermentation liquor, 5-10 parts of white peony root extract, 1-5 parts of inonotus obliquus extract and 0.1-1 part of hyaluronic acid composition;
the fermentation liquor is obtained by inoculating strains in the tea; the bacterial species is selected from bifidobacteria;
the hyaluronic acid composition comprises hyaluronate with the molecular weight of 1000-1800kDa, hydrolyzed hyaluronate with the molecular weight of less than 10kDa and acetylated hyaluronate.
2. The composition of claim 1, wherein the mass ratio of the hyaluronic acid salt, the hydrolyzed hyaluronic acid salt, and the acetylated hyaluronic acid salt is 1 (0.95-1.05) to (0.95-1.05).
3. The composition of claim 1, wherein the white peony extract is an extract of white peony root with water and/or alcohol.
4. The composition of claim 3, wherein the alcohol is at least one of methanol, ethanol, propanol, or butanol.
5. A process for the preparation of a composition according to any one of claims 1 to 4, characterized in that it comprises the following steps:
mixing the components, and heating to obtain the composition.
6. A cosmetic comprising the composition according to any one of claims 1 to 4.
7. The cosmetic according to claim 6, wherein the composition is present in an amount of 1 to 10% by mass.
8. Use of a composition according to any one of claims 1 to 4 for the preparation of a product for improving dark circles.
CN202111444022.3A 2021-11-30 2021-11-30 Composition for improving dark eye circles and preparation method and application thereof Active CN114028291B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111444022.3A CN114028291B (en) 2021-11-30 2021-11-30 Composition for improving dark eye circles and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111444022.3A CN114028291B (en) 2021-11-30 2021-11-30 Composition for improving dark eye circles and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114028291A CN114028291A (en) 2022-02-11
CN114028291B true CN114028291B (en) 2023-02-03

Family

ID=80139428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111444022.3A Active CN114028291B (en) 2021-11-30 2021-11-30 Composition for improving dark eye circles and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114028291B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643600A (en) * 2024-01-29 2024-03-05 黑龙江中医药大学 Inonotus obliquus active component extract and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080094456A (en) * 2007-04-20 2008-10-23 주식회사 엘지생활건강 Whitening cosmetic composition
CN110711157A (en) * 2018-07-13 2020-01-21 迈健医药科技无锡有限公司 Eye cream for removing dark eye circles and preparation method thereof
CN112190507A (en) * 2020-10-28 2021-01-08 广州品赫化妆品有限公司 Composition containing poria cocos extract for removing dark circles and resisting wrinkles as well as preparation method and application of composition
CN112675089A (en) * 2021-01-04 2021-04-20 广东名兰化妆品制造有限公司 Eye cream for removing dark circles, eliminating pouches, resisting wrinkles and smoothing wrinkles and preparation method thereof
CN112888425A (en) * 2018-10-26 2021-06-01 巴斯夫美容护理法国公司 Novel cosmetic and dermatological use of an extract of the fungus Inonotus obliquus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080094456A (en) * 2007-04-20 2008-10-23 주식회사 엘지생활건강 Whitening cosmetic composition
CN110711157A (en) * 2018-07-13 2020-01-21 迈健医药科技无锡有限公司 Eye cream for removing dark eye circles and preparation method thereof
CN112888425A (en) * 2018-10-26 2021-06-01 巴斯夫美容护理法国公司 Novel cosmetic and dermatological use of an extract of the fungus Inonotus obliquus
CN112190507A (en) * 2020-10-28 2021-01-08 广州品赫化妆品有限公司 Composition containing poria cocos extract for removing dark circles and resisting wrinkles as well as preparation method and application of composition
CN112675089A (en) * 2021-01-04 2021-04-20 广东名兰化妆品制造有限公司 Eye cream for removing dark circles, eliminating pouches, resisting wrinkles and smoothing wrinkles and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
雪之谜 桦褐孔菌眼部精华液;广东沐轩生物科技有限公司;《http://ftba.nmpa.gov.cn:8181/ftban/itownet/hzp_ba/fw/pz.jsp?processid=2016110217241232w5e&nid=2016110217241232w5e》;国产非特殊用途化妆品信息平台;20161108;网页正文 *

Also Published As

Publication number Publication date
CN114028291A (en) 2022-02-11

Similar Documents

Publication Publication Date Title
CN105963153B (en) Active compound and cosmetics or skin care item comprising blue copper victory peptide
CN109464378B (en) Multi-effect repair eye cream and preparation method thereof
CN106265360B (en) A kind of facial cleanser of the product containing fermentation of seaweed and preparation method thereof
CN108113914B (en) Essence cream without essence and preservative and preparation method thereof
CN111603434B (en) Composition for improving skin wrinkles and cosmetic thereof
CN110755328A (en) Beautifying, moisturizing and repairing composition and application thereof
CN108670901B (en) Skin softening lotion with macadamia nut protein peptide and green tangerine peel extract as active ingredients and preparation method thereof
CN110368337B (en) Facial mask containing rose hip extract and preparation method
CN114028291B (en) Composition for improving dark eye circles and preparation method and application thereof
CN105310972A (en) Anti-wrinkle skin care product
CN116869898A (en) Protective cream for sensitive skin with enhanced barrier and preparation method thereof
CN104188859A (en) Anti-wrinkle skin-tendering emulsion containing natural component extracts and preparation method thereof
CN115518012B (en) Composition with effects of inhibiting melanin protein and improving black eye and eye pouch and application thereof
CN110680775A (en) Pure whitening, moisturizing and hydrating liquid and preparation method thereof
CN112972314B (en) Eye repair composition and preparation method and application thereof
CN114317651A (en) Polygonatum sibiricum polypeptide, preparation method and application thereof
CN110623910A (en) Ginseng and pilose antler skin-moistening cream
CN107802516A (en) A kind of long-acting preserving moisture and protecting skin Essence
CN114652628A (en) Anti-aging cream for beautifying chest and body and enhancing skin immune barrier and preparation method thereof
CN114712269A (en) Anti-aging essential oil composition and preparation method and application thereof
KR101154772B1 (en) Cosmetic composition containing the zizyphus jujuba fruit extract and walnut extract for moisturizing effect on the skin
KR102157210B1 (en) The functional cosmetic composition comprising extract of natural micro organism-fermented black ginseng
CN109646359B (en) Rose-agaric mud membrane paste with effects of cleaning, purifying, maintaining beauty and keeping young and preparation method thereof
CN112675071A (en) Wool keratin freeze-dried mask and preparation method and application thereof
JP2004035425A (en) Ameliorant for dropsy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant